Even when menopause is finally noticed, it’s still framed as a market inefficiency. That’s the problem. Women’s health doesn’t need better venture decks. It needs people who can actually read what women’s bodies are saying.
I hear you. If we start with venture decks instead of women’s bodies, we’re just repeating the problem. My argument here is that the mispricing exists because biology was ignored in the first place. Menopause is a biological inflection point that reshapes risk and behavior. Capital hasn’t caught up, but it should because the data is already there, waiting to be acted on.
Even when menopause is finally noticed, it’s still framed as a market inefficiency. That’s the problem. Women’s health doesn’t need better venture decks. It needs people who can actually read what women’s bodies are saying.
I hear you. If we start with venture decks instead of women’s bodies, we’re just repeating the problem. My argument here is that the mispricing exists because biology was ignored in the first place. Menopause is a biological inflection point that reshapes risk and behavior. Capital hasn’t caught up, but it should because the data is already there, waiting to be acted on.